Geld/Brief | 26,14 $ / 31,69 $ |
Spread | +21,23% |
Schluss Vortag | 29,32 $ |
Gehandelte Stücke | 3.142.548 |
Tagesvolumen Vortag | 1.363.218,67 $ |
Tagestief 29,06 $ Tageshoch 29,14 $ | |
52W-Tief 22,90 $ 52W-Hoch 36,44 $ | |
Jahrestief 25,56 $ Jahreshoch 36,44 $ |
Geschäftsjahr | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Dividende je Aktie | - | - | - | - | - |
Dividendenrendite | - | - | - | - | - |
Gewinn je Aktie | - | - | - | - | - |
KGV (Kurs/Gewinn) | - | - | - | - | - |
Buchwert je Aktie | 7,53 € |
Cashflow je Aktie | 0,64 € |
30 Tage Vola | 26,88 |
90 Tage Vola | 35,86 |
KBV (Kurs/Buchwert) | 3,92 |
KCV (Kurs/Cashflow) | 46,11 |
Enterprise Value | 3,54 Mrd € |
Enterprise Value/EBITDA | 8,80 |
180 Tage Vola | 34,26 |
250 Tage Vola | 33,62 |
Zeit | Titel | Quelle |
02.06.25 | Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | PR Newswire |
02.06.25 | Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | PR Newswire |
02.06.25 | Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences | PR Newswire |
02.06.25 | Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences | PR Newswire |
29.05.25 | Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 | PR Newswire |
29.05.25 | Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 | PR Newswire |
Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
---|---|---|---|---|---|
Frankfurt | 25,00 € | 0 % | 25,00 € | 20.06.25 | |
München | 25,20 € | 0 % | 25,20 € | 20.06.25 | |
Stuttgart | 25,00 € | -0,79% | 25,20 € | 20.06.25 | |
L&S RT | 25,30 € | 0 % | 25,30 € | 19:04 | |
NYSE | 29,07 $ | -0,84% | 29,315 $ | 20.06.25 | |
Nasdaq | 29,09 $ | -0,78% | 29,32 $ | 20.06.25 | |
AMEX | 29,10 $ | -2,28% | 29,78 $ | 20.06.25 | |
Tradegate | 25,60 € | +0,79% | 25,40 € | 17.06.25 | |
Quotrix | 25,40 € | -0,78% | 25,60 € | 20.06.25 |
Datum | Kurs | Volumen |
---|---|---|
20.06.25 | 29,09 | 78,1 M |
18.06.25 | 29,33 | 1,36 M |
17.06.25 | 29,77 | 1,85 M |
16.06.25 | 29,42 | 1,98 M |
13.06.25 | 29,83 | 1,46 M |
Zeitraum | Kurs | % |
---|---|---|
1 Woche | 29,83 $ | -2,48% |
1 Monat | 31,67 $ | -8,15% |
6 Monate | 29,71 $ | -2,09% |
1 Jahr | 25,045 $ | +16,15% |
5 Jahre | 18,35 $ | +58,53% |
Fast Track Status für Nemvaleukin
https://www.benzinga.com/general/biotech/21/08/22271688/alkermes-receives-fda-fast-track-status-for-mucosal-melanoma-immunotherapy
Zulassung für ALKS 3831
https://endpts.com/alkermes-wins-fda-nod-for-combo-med-with-antipsychotic-olanzapine-this-time-without-the-weight-gain-red-flags/